ADC Therapeutics (ADCT) Set to Announce Quarterly Earnings on Thursday

ADC Therapeutics (NYSE:ADCT) is set to issue its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

ADC Therapeutics (NYSE:ADCT) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. The business had revenue of $17.41 million for the quarter, compared to analysts’ expectations of $19.06 million. During the same quarter in the prior year, the company posted ($0.58) earnings per share. On average, analysts expect ADC Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ADC Therapeutics Stock Up 1.7 %

Shares of NYSE:ADCT traded up $0.05 during midday trading on Tuesday, reaching $3.07. 171,692 shares of the company’s stock were exchanged, compared to its average volume of 632,504. The firm’s 50 day simple moving average is $3.01 and its two-hundred day simple moving average is $3.35. ADC Therapeutics has a fifty-two week low of $0.36 and a fifty-two week high of $6.04.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ADCT. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of ADC Therapeutics in a research note on Thursday, August 8th. Royal Bank of Canada reiterated an “outperform” rating and issued a $8.00 target price on shares of ADC Therapeutics in a report on Wednesday, August 7th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

ADC Therapeutics Company Profile

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.